nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—HRH1—atherosclerosis	0.364	1	CbGaD
Risperidone—CYP3A7-CYP3A51P—Simvastatin—atherosclerosis	0.0292	0.0807	CbGbCtD
Risperidone—CYP3A7—Simvastatin—atherosclerosis	0.0292	0.0807	CbGbCtD
Risperidone—CYP3A7—Lovastatin—atherosclerosis	0.0286	0.079	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Lovastatin—atherosclerosis	0.0286	0.079	CbGbCtD
Risperidone—CYP3A5—Rosuvastatin—atherosclerosis	0.0236	0.0651	CbGbCtD
Risperidone—CYP3A5—Simvastatin—atherosclerosis	0.0219	0.0606	CbGbCtD
Risperidone—CYP3A5—Lovastatin—atherosclerosis	0.0214	0.0593	CbGbCtD
Risperidone—CYP3A5—Pravastatin—atherosclerosis	0.0214	0.0593	CbGbCtD
Risperidone—CYP2D6—Niacin—atherosclerosis	0.017	0.047	CbGbCtD
Risperidone—ABCB1—Ezetimibe—atherosclerosis	0.0153	0.0424	CbGbCtD
Risperidone—ABCB1—Simvastatin—atherosclerosis	0.0143	0.0394	CbGbCtD
Risperidone—ABCB1—Lovastatin—atherosclerosis	0.014	0.0386	CbGbCtD
Risperidone—ABCB1—Pravastatin—atherosclerosis	0.014	0.0386	CbGbCtD
Risperidone—CYP2D6—Simvastatin—atherosclerosis	0.0134	0.0371	CbGbCtD
Risperidone—CYP2D6—Pravastatin—atherosclerosis	0.0132	0.0363	CbGbCtD
Risperidone—CYP2D6—Lovastatin—atherosclerosis	0.0132	0.0363	CbGbCtD
Risperidone—CYP3A4—Rosuvastatin—atherosclerosis	0.00919	0.0254	CbGbCtD
Risperidone—CYP3A4—Ezetimibe—atherosclerosis	0.00919	0.0254	CbGbCtD
Risperidone—CYP3A4—Simvastatin—atherosclerosis	0.00855	0.0236	CbGbCtD
Risperidone—CYP3A4—Lovastatin—atherosclerosis	0.00836	0.0231	CbGbCtD
Risperidone—CYP3A4—Pravastatin—atherosclerosis	0.00836	0.0231	CbGbCtD
Risperidone—HTR2A—arteriole—atherosclerosis	0.00245	0.0909	CbGeAlD
Risperidone—HTR7—vein—atherosclerosis	0.00235	0.0869	CbGeAlD
Risperidone—Paliperidone—HRH1—atherosclerosis	0.00177	0.588	CrCbGaD
Risperidone—HTR2A—vein—atherosclerosis	0.00146	0.0542	CbGeAlD
Risperidone—HTR1B—artery—atherosclerosis	0.00124	0.0459	CbGeAlD
Risperidone—Iloperidone—HRH1—atherosclerosis	0.00124	0.412	CrCbGaD
Risperidone—HTR1D—artery—atherosclerosis	0.0012	0.0444	CbGeAlD
Risperidone—HTR2A—hindlimb—atherosclerosis	0.000973	0.036	CbGeAlD
Risperidone—HTR1B—blood vessel—atherosclerosis	0.000966	0.0358	CbGeAlD
Risperidone—HTR7—artery—atherosclerosis	0.000956	0.0354	CbGeAlD
Risperidone—HTR1D—blood vessel—atherosclerosis	0.000935	0.0346	CbGeAlD
Risperidone—HTR2A—appendage—atherosclerosis	0.000834	0.0309	CbGeAlD
Risperidone—HTR7—endothelium—atherosclerosis	0.000808	0.0299	CbGeAlD
Risperidone—HTR7—blood vessel—atherosclerosis	0.000745	0.0276	CbGeAlD
Risperidone—H1F0—connective tissue—atherosclerosis	0.000619	0.0229	CbGeAlD
Risperidone—HTR2A—artery—atherosclerosis	0.000596	0.0221	CbGeAlD
Risperidone—H1F0—cardiovascular system—atherosclerosis	0.000538	0.0199	CbGeAlD
Risperidone—HTR2A—endothelium—atherosclerosis	0.000504	0.0186	CbGeAlD
Risperidone—HTR1D—connective tissue—atherosclerosis	0.000479	0.0177	CbGeAlD
Risperidone—H1F0—adipose tissue—atherosclerosis	0.000475	0.0176	CbGeAlD
Risperidone—HTR2A—blood vessel—atherosclerosis	0.000464	0.0172	CbGeAlD
Risperidone—CYP3A7—liver—atherosclerosis	0.000449	0.0166	CbGeAlD
Risperidone—HTR1B—cardiovascular system—atherosclerosis	0.000431	0.016	CbGeAlD
Risperidone—HTR1D—cardiovascular system—atherosclerosis	0.000417	0.0154	CbGeAlD
Risperidone—HTR2B—cardiovascular system—atherosclerosis	0.000388	0.0144	CbGeAlD
Risperidone—CYP3A7-CYP3A51P—liver—atherosclerosis	0.000382	0.0141	CbGeAlD
Risperidone—HTR7—connective tissue—atherosclerosis	0.000382	0.0141	CbGeAlD
Risperidone—HTR1A—cardiovascular system—atherosclerosis	0.000348	0.0129	CbGeAlD
Risperidone—HTR2B—adipose tissue—atherosclerosis	0.000342	0.0127	CbGeAlD
Risperidone—H1F0—liver—atherosclerosis	0.000333	0.0123	CbGeAlD
Risperidone—HTR7—cardiovascular system—atherosclerosis	0.000332	0.0123	CbGeAlD
Risperidone—ADRA1A—cardiovascular system—atherosclerosis	0.00032	0.0119	CbGeAlD
Risperidone—KCNH2—cardiovascular system—atherosclerosis	0.000309	0.0115	CbGeAlD
Risperidone—ABCB1—blood vessel—atherosclerosis	0.000304	0.0113	CbGeAlD
Risperidone—HRH1—connective tissue—atherosclerosis	0.000285	0.0106	CbGeAlD
Risperidone—ADRA1A—adipose tissue—atherosclerosis	0.000283	0.0105	CbGeAlD
Risperidone—ADRA2A—connective tissue—atherosclerosis	0.00028	0.0104	CbGeAlD
Risperidone—ADRA2C—adipose tissue—atherosclerosis	0.000269	0.00997	CbGeAlD
Risperidone—HTR2A—connective tissue—atherosclerosis	0.000238	0.00882	CbGeAlD
Risperidone—CYP3A5—adipose tissue—atherosclerosis	0.000225	0.00834	CbGeAlD
Risperidone—HRH1—adipose tissue—atherosclerosis	0.000219	0.0081	CbGeAlD
Risperidone—ADRA2A—adipose tissue—atherosclerosis	0.000215	0.00796	CbGeAlD
Risperidone—HTR2A—cardiovascular system—atherosclerosis	0.000207	0.00767	CbGeAlD
Risperidone—HTR7—liver—atherosclerosis	0.000205	0.00761	CbGeAlD
Risperidone—ADRA1A—liver—atherosclerosis	0.000198	0.00734	CbGeAlD
Risperidone—ADRA2C—liver—atherosclerosis	0.000189	0.00699	CbGeAlD
Risperidone—CYP3A5—liver—atherosclerosis	0.000158	0.00585	CbGeAlD
Risperidone—Muscle spasms—Simvastatin—atherosclerosis	0.000153	0.000979	CcSEcCtD
Risperidone—Vertigo—Lovastatin—atherosclerosis	0.000153	0.000978	CcSEcCtD
Risperidone—Angioedema—Ezetimibe—atherosclerosis	0.000152	0.000975	CcSEcCtD
Risperidone—Angiopathy—Niacin—atherosclerosis	0.000152	0.000974	CcSEcCtD
Risperidone—Leukopenia—Lovastatin—atherosclerosis	0.000152	0.000974	CcSEcCtD
Risperidone—Chills—Niacin—atherosclerosis	0.00015	0.000963	CcSEcCtD
Risperidone—Malaise—Ezetimibe—atherosclerosis	0.00015	0.000963	CcSEcCtD
Risperidone—Vision blurred—Simvastatin—atherosclerosis	0.00015	0.000959	CcSEcCtD
Risperidone—Arrhythmia—Niacin—atherosclerosis	0.00015	0.000959	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000149	0.000955	CcSEcCtD
Risperidone—Tremor—Simvastatin—atherosclerosis	0.000149	0.000954	CcSEcCtD
Risperidone—Alopecia—Niacin—atherosclerosis	0.000148	0.000949	CcSEcCtD
Risperidone—Chills—Pravastatin—atherosclerosis	0.000148	0.000949	CcSEcCtD
Risperidone—Insomnia—Rosuvastatin—atherosclerosis	0.000148	0.000948	CcSEcCtD
Risperidone—Ill-defined disorder—Simvastatin—atherosclerosis	0.000147	0.000945	CcSEcCtD
Risperidone—Arrhythmia—Pravastatin—atherosclerosis	0.000147	0.000944	CcSEcCtD
Risperidone—Palpitations—Ezetimibe—atherosclerosis	0.000147	0.000943	CcSEcCtD
Risperidone—Paraesthesia—Rosuvastatin—atherosclerosis	0.000147	0.000941	CcSEcCtD
Risperidone—Anaemia—Simvastatin—atherosclerosis	0.000147	0.000941	CcSEcCtD
Risperidone—Erythema—Niacin—atherosclerosis	0.000146	0.000935	CcSEcCtD
Risperidone—Malnutrition—Niacin—atherosclerosis	0.000146	0.000935	CcSEcCtD
Risperidone—Alopecia—Pravastatin—atherosclerosis	0.000146	0.000934	CcSEcCtD
Risperidone—Cough—Ezetimibe—atherosclerosis	0.000145	0.000931	CcSEcCtD
Risperidone—Angioedema—Simvastatin—atherosclerosis	0.000145	0.00093	CcSEcCtD
Risperidone—Myalgia—Lovastatin—atherosclerosis	0.000145	0.000927	CcSEcCtD
Risperidone—Chest pain—Lovastatin—atherosclerosis	0.000145	0.000927	CcSEcCtD
Risperidone—Arthralgia—Lovastatin—atherosclerosis	0.000145	0.000927	CcSEcCtD
Risperidone—Anxiety—Lovastatin—atherosclerosis	0.000144	0.000923	CcSEcCtD
Risperidone—Dyspepsia—Rosuvastatin—atherosclerosis	0.000144	0.000923	CcSEcCtD
Risperidone—Hypertension—Ezetimibe—atherosclerosis	0.000144	0.000922	CcSEcCtD
Risperidone—Flatulence—Niacin—atherosclerosis	0.000144	0.000921	CcSEcCtD
Risperidone—Malaise—Simvastatin—atherosclerosis	0.000143	0.000918	CcSEcCtD
Risperidone—Tension—Niacin—atherosclerosis	0.000143	0.000917	CcSEcCtD
Risperidone—Discomfort—Lovastatin—atherosclerosis	0.000143	0.000915	CcSEcCtD
Risperidone—Vertigo—Simvastatin—atherosclerosis	0.000143	0.000915	CcSEcCtD
Risperidone—Leukopenia—Simvastatin—atherosclerosis	0.000142	0.000911	CcSEcCtD
Risperidone—Chest pain—Ezetimibe—atherosclerosis	0.000142	0.000909	CcSEcCtD
Risperidone—Arthralgia—Ezetimibe—atherosclerosis	0.000142	0.000909	CcSEcCtD
Risperidone—Myalgia—Ezetimibe—atherosclerosis	0.000142	0.000909	CcSEcCtD
Risperidone—Nervousness—Niacin—atherosclerosis	0.000142	0.000908	CcSEcCtD
Risperidone—Flatulence—Pravastatin—atherosclerosis	0.000141	0.000907	CcSEcCtD
Risperidone—Dry mouth—Lovastatin—atherosclerosis	0.000141	0.000906	CcSEcCtD
Risperidone—Tension—Pravastatin—atherosclerosis	0.000141	0.000903	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000141	0.000903	CcSEcCtD
Risperidone—Dysgeusia—Pravastatin—atherosclerosis	0.000141	0.000901	CcSEcCtD
Risperidone—Muscle spasms—Niacin—atherosclerosis	0.00014	0.000899	CcSEcCtD
Risperidone—Discomfort—Ezetimibe—atherosclerosis	0.00014	0.000898	CcSEcCtD
Risperidone—Pain—Rosuvastatin—atherosclerosis	0.00014	0.000896	CcSEcCtD
Risperidone—Constipation—Rosuvastatin—atherosclerosis	0.00014	0.000896	CcSEcCtD
Risperidone—Confusional state—Lovastatin—atherosclerosis	0.00014	0.000896	CcSEcCtD
Risperidone—Nervousness—Pravastatin—atherosclerosis	0.000139	0.000894	CcSEcCtD
Risperidone—Dry mouth—Ezetimibe—atherosclerosis	0.000139	0.000889	CcSEcCtD
Risperidone—Anaphylactic shock—Lovastatin—atherosclerosis	0.000139	0.000888	CcSEcCtD
Risperidone—Muscle spasms—Pravastatin—atherosclerosis	0.000138	0.000885	CcSEcCtD
Risperidone—Infection—Lovastatin—atherosclerosis	0.000138	0.000882	CcSEcCtD
Risperidone—Vision blurred—Niacin—atherosclerosis	0.000137	0.000881	CcSEcCtD
Risperidone—Confusional state—Ezetimibe—atherosclerosis	0.000137	0.000878	CcSEcCtD
Risperidone—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000136	0.000871	CcSEcCtD
Risperidone—ABCB1—cardiovascular system—atherosclerosis	0.000136	0.00503	CbGeAlD
Risperidone—Thrombocytopenia—Lovastatin—atherosclerosis	0.000136	0.00087	CcSEcCtD
Risperidone—Vision blurred—Pravastatin—atherosclerosis	0.000135	0.000867	CcSEcCtD
Risperidone—Arthralgia—Simvastatin—atherosclerosis	0.000135	0.000867	CcSEcCtD
Risperidone—Myalgia—Simvastatin—atherosclerosis	0.000135	0.000867	CcSEcCtD
Risperidone—Chest pain—Simvastatin—atherosclerosis	0.000135	0.000867	CcSEcCtD
Risperidone—Infection—Ezetimibe—atherosclerosis	0.000135	0.000866	CcSEcCtD
Risperidone—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000135	0.000864	CcSEcCtD
Risperidone—Anxiety—Simvastatin—atherosclerosis	0.000135	0.000864	CcSEcCtD
Risperidone—Tremor—Pravastatin—atherosclerosis	0.000135	0.000862	CcSEcCtD
Risperidone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000134	0.000857	CcSEcCtD
Risperidone—Discomfort—Simvastatin—atherosclerosis	0.000134	0.000856	CcSEcCtD
Risperidone—Nervous system disorder—Ezetimibe—atherosclerosis	0.000133	0.000854	CcSEcCtD
Risperidone—Angioedema—Niacin—atherosclerosis	0.000133	0.000854	CcSEcCtD
Risperidone—Ill-defined disorder—Pravastatin—atherosclerosis	0.000133	0.000854	CcSEcCtD
Risperidone—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000133	0.000853	CcSEcCtD
Risperidone—Anaemia—Pravastatin—atherosclerosis	0.000133	0.000851	CcSEcCtD
Risperidone—Anorexia—Lovastatin—atherosclerosis	0.000132	0.000847	CcSEcCtD
Risperidone—Skin disorder—Ezetimibe—atherosclerosis	0.000132	0.000846	CcSEcCtD
Risperidone—Angioedema—Pravastatin—atherosclerosis	0.000131	0.000841	CcSEcCtD
Risperidone—Vertigo—Niacin—atherosclerosis	0.000131	0.00084	CcSEcCtD
Risperidone—Syncope—Niacin—atherosclerosis	0.000131	0.000838	CcSEcCtD
Risperidone—Confusional state—Simvastatin—atherosclerosis	0.000131	0.000838	CcSEcCtD
Risperidone—Leukopenia—Niacin—atherosclerosis	0.000131	0.000837	CcSEcCtD
Risperidone—Urticaria—Rosuvastatin—atherosclerosis	0.00013	0.000833	CcSEcCtD
Risperidone—Anaphylactic shock—Simvastatin—atherosclerosis	0.00013	0.000831	CcSEcCtD
Risperidone—Oedema—Simvastatin—atherosclerosis	0.00013	0.000831	CcSEcCtD
Risperidone—Malaise—Pravastatin—atherosclerosis	0.000129	0.00083	CcSEcCtD
Risperidone—Abdominal pain—Rosuvastatin—atherosclerosis	0.000129	0.000829	CcSEcCtD
Risperidone—Vertigo—Pravastatin—atherosclerosis	0.000129	0.000827	CcSEcCtD
Risperidone—Palpitations—Niacin—atherosclerosis	0.000129	0.000826	CcSEcCtD
Risperidone—Infection—Simvastatin—atherosclerosis	0.000129	0.000825	CcSEcCtD
Risperidone—Leukopenia—Pravastatin—atherosclerosis	0.000129	0.000824	CcSEcCtD
Risperidone—Loss of consciousness—Niacin—atherosclerosis	0.000128	0.000822	CcSEcCtD
Risperidone—HTR2A—liver—atherosclerosis	0.000128	0.00474	CbGeAlD
Risperidone—Cough—Niacin—atherosclerosis	0.000127	0.000816	CcSEcCtD
Risperidone—Thrombocytopenia—Simvastatin—atherosclerosis	0.000127	0.000813	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000126	0.000809	CcSEcCtD
Risperidone—Insomnia—Lovastatin—atherosclerosis	0.000125	0.000803	CcSEcCtD
Risperidone—Cough—Pravastatin—atherosclerosis	0.000125	0.000803	CcSEcCtD
Risperidone—Paraesthesia—Lovastatin—atherosclerosis	0.000124	0.000798	CcSEcCtD
Risperidone—Myalgia—Niacin—atherosclerosis	0.000124	0.000796	CcSEcCtD
Risperidone—Arthralgia—Niacin—atherosclerosis	0.000124	0.000796	CcSEcCtD
Risperidone—Hypertension—Pravastatin—atherosclerosis	0.000124	0.000795	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000124	0.000794	CcSEcCtD
Risperidone—Anorexia—Simvastatin—atherosclerosis	0.000124	0.000792	CcSEcCtD
Risperidone—Dyspnoea—Lovastatin—atherosclerosis	0.000124	0.000792	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000123	0.00079	CcSEcCtD
Risperidone—Insomnia—Ezetimibe—atherosclerosis	0.000123	0.000788	CcSEcCtD
Risperidone—Chest pain—Pravastatin—atherosclerosis	0.000122	0.000784	CcSEcCtD
Risperidone—Myalgia—Pravastatin—atherosclerosis	0.000122	0.000784	CcSEcCtD
Risperidone—Arthralgia—Pravastatin—atherosclerosis	0.000122	0.000784	CcSEcCtD
Risperidone—Paraesthesia—Ezetimibe—atherosclerosis	0.000122	0.000782	CcSEcCtD
Risperidone—Dyspepsia—Lovastatin—atherosclerosis	0.000122	0.000782	CcSEcCtD
Risperidone—Anxiety—Pravastatin—atherosclerosis	0.000122	0.000781	CcSEcCtD
Risperidone—Dry mouth—Niacin—atherosclerosis	0.000121	0.000778	CcSEcCtD
Risperidone—Dyspnoea—Ezetimibe—atherosclerosis	0.000121	0.000777	CcSEcCtD
Risperidone—Discomfort—Pravastatin—atherosclerosis	0.000121	0.000774	CcSEcCtD
Risperidone—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00012	0.000772	CcSEcCtD
Risperidone—Decreased appetite—Lovastatin—atherosclerosis	0.00012	0.000772	CcSEcCtD
Risperidone—ABCB1—adipose tissue—atherosclerosis	0.00012	0.00443	CbGeAlD
Risperidone—Dyspepsia—Ezetimibe—atherosclerosis	0.00012	0.000767	CcSEcCtD
Risperidone—Fatigue—Lovastatin—atherosclerosis	0.000119	0.000766	CcSEcCtD
Risperidone—Anaphylactic shock—Niacin—atherosclerosis	0.000119	0.000763	CcSEcCtD
Risperidone—Oedema—Niacin—atherosclerosis	0.000119	0.000763	CcSEcCtD
Risperidone—CYP3A4—liver—atherosclerosis	0.000119	0.00439	CbGeAlD
Risperidone—Constipation—Lovastatin—atherosclerosis	0.000119	0.00076	CcSEcCtD
Risperidone—Pain—Lovastatin—atherosclerosis	0.000119	0.00076	CcSEcCtD
Risperidone—Confusional state—Pravastatin—atherosclerosis	0.000118	0.000757	CcSEcCtD
Risperidone—Decreased appetite—Ezetimibe—atherosclerosis	0.000118	0.000757	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000118	0.000757	CcSEcCtD
Risperidone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000117	0.000752	CcSEcCtD
Risperidone—Asthenia—Rosuvastatin—atherosclerosis	0.000117	0.000752	CcSEcCtD
Risperidone—Insomnia—Simvastatin—atherosclerosis	0.000117	0.000751	CcSEcCtD
Risperidone—Anaphylactic shock—Pravastatin—atherosclerosis	0.000117	0.000751	CcSEcCtD
Risperidone—Oedema—Pravastatin—atherosclerosis	0.000117	0.000751	CcSEcCtD
Risperidone—Fatigue—Ezetimibe—atherosclerosis	0.000117	0.000751	CcSEcCtD
Risperidone—Shock—Niacin—atherosclerosis	0.000117	0.000751	CcSEcCtD
Risperidone—CYP2D6—liver—atherosclerosis	0.000117	0.00432	CbGeAlD
Risperidone—Infection—Pravastatin—atherosclerosis	0.000116	0.000746	CcSEcCtD
Risperidone—Paraesthesia—Simvastatin—atherosclerosis	0.000116	0.000746	CcSEcCtD
Risperidone—Pain—Ezetimibe—atherosclerosis	0.000116	0.000745	CcSEcCtD
Risperidone—Constipation—Ezetimibe—atherosclerosis	0.000116	0.000745	CcSEcCtD
Risperidone—Tachycardia—Niacin—atherosclerosis	0.000116	0.000745	CcSEcCtD
Risperidone—Pruritus—Rosuvastatin—atherosclerosis	0.000116	0.000742	CcSEcCtD
Risperidone—Skin disorder—Niacin—atherosclerosis	0.000116	0.000741	CcSEcCtD
Risperidone—Dyspnoea—Simvastatin—atherosclerosis	0.000116	0.000741	CcSEcCtD
Risperidone—Hyperhidrosis—Niacin—atherosclerosis	0.000115	0.000737	CcSEcCtD
Risperidone—Thrombocytopenia—Pravastatin—atherosclerosis	0.000115	0.000735	CcSEcCtD
Risperidone—Feeling abnormal—Lovastatin—atherosclerosis	0.000114	0.000732	CcSEcCtD
Risperidone—Dyspepsia—Simvastatin—atherosclerosis	0.000114	0.000731	CcSEcCtD
Risperidone—Anorexia—Niacin—atherosclerosis	0.000113	0.000727	CcSEcCtD
Risperidone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000113	0.000726	CcSEcCtD
Risperidone—Hyperhidrosis—Pravastatin—atherosclerosis	0.000113	0.000726	CcSEcCtD
Risperidone—Decreased appetite—Simvastatin—atherosclerosis	0.000113	0.000722	CcSEcCtD
Risperidone—Feeling abnormal—Ezetimibe—atherosclerosis	0.000112	0.000718	CcSEcCtD
Risperidone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000112	0.000717	CcSEcCtD
Risperidone—Diarrhoea—Rosuvastatin—atherosclerosis	0.000112	0.000717	CcSEcCtD
Risperidone—Fatigue—Simvastatin—atherosclerosis	0.000112	0.000716	CcSEcCtD
Risperidone—Anorexia—Pravastatin—atherosclerosis	0.000112	0.000716	CcSEcCtD
Risperidone—Hypotension—Niacin—atherosclerosis	0.000111	0.000713	CcSEcCtD
Risperidone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000111	0.000712	CcSEcCtD
Risperidone—Pain—Simvastatin—atherosclerosis	0.000111	0.00071	CcSEcCtD
Risperidone—Constipation—Simvastatin—atherosclerosis	0.000111	0.00071	CcSEcCtD
Risperidone—Urticaria—Lovastatin—atherosclerosis	0.00011	0.000706	CcSEcCtD
Risperidone—Abdominal pain—Lovastatin—atherosclerosis	0.00011	0.000702	CcSEcCtD
Risperidone—Body temperature increased—Lovastatin—atherosclerosis	0.00011	0.000702	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000108	0.000695	CcSEcCtD
Risperidone—Dizziness—Rosuvastatin—atherosclerosis	0.000108	0.000693	CcSEcCtD
Risperidone—Urticaria—Ezetimibe—atherosclerosis	0.000108	0.000692	CcSEcCtD
Risperidone—Insomnia—Niacin—atherosclerosis	0.000108	0.00069	CcSEcCtD
Risperidone—Abdominal pain—Ezetimibe—atherosclerosis	0.000107	0.000689	CcSEcCtD
Risperidone—Body temperature increased—Ezetimibe—atherosclerosis	0.000107	0.000689	CcSEcCtD
Risperidone—Paraesthesia—Niacin—atherosclerosis	0.000107	0.000685	CcSEcCtD
Risperidone—Feeling abnormal—Simvastatin—atherosclerosis	0.000107	0.000685	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000107	0.000684	CcSEcCtD
Risperidone—Dyspnoea—Niacin—atherosclerosis	0.000106	0.00068	CcSEcCtD
Risperidone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000106	0.000679	CcSEcCtD
Risperidone—Insomnia—Pravastatin—atherosclerosis	0.000106	0.000679	CcSEcCtD
Risperidone—Somnolence—Niacin—atherosclerosis	0.000106	0.000678	CcSEcCtD
Risperidone—Paraesthesia—Pravastatin—atherosclerosis	0.000105	0.000674	CcSEcCtD
Risperidone—Dyspepsia—Niacin—atherosclerosis	0.000105	0.000672	CcSEcCtD
Risperidone—Dyspnoea—Pravastatin—atherosclerosis	0.000104	0.00067	CcSEcCtD
Risperidone—Decreased appetite—Niacin—atherosclerosis	0.000103	0.000663	CcSEcCtD
Risperidone—Dyspepsia—Pravastatin—atherosclerosis	0.000103	0.000661	CcSEcCtD
Risperidone—Rash—Rosuvastatin—atherosclerosis	0.000103	0.000661	CcSEcCtD
Risperidone—Dermatitis—Rosuvastatin—atherosclerosis	0.000103	0.00066	CcSEcCtD
Risperidone—Urticaria—Simvastatin—atherosclerosis	0.000103	0.00066	CcSEcCtD
Risperidone—Gastrointestinal disorder—Niacin—atherosclerosis	0.000103	0.000659	CcSEcCtD
Risperidone—Abdominal pain—Simvastatin—atherosclerosis	0.000102	0.000657	CcSEcCtD
Risperidone—Body temperature increased—Simvastatin—atherosclerosis	0.000102	0.000657	CcSEcCtD
Risperidone—Headache—Rosuvastatin—atherosclerosis	0.000102	0.000657	CcSEcCtD
Risperidone—Hypersensitivity—Lovastatin—atherosclerosis	0.000102	0.000654	CcSEcCtD
Risperidone—Decreased appetite—Pravastatin—atherosclerosis	0.000102	0.000653	CcSEcCtD
Risperidone—Pain—Niacin—atherosclerosis	0.000102	0.000652	CcSEcCtD
Risperidone—Fatigue—Pravastatin—atherosclerosis	0.000101	0.000648	CcSEcCtD
Risperidone—Pain—Pravastatin—atherosclerosis	0.0001	0.000642	CcSEcCtD
Risperidone—Constipation—Pravastatin—atherosclerosis	0.0001	0.000642	CcSEcCtD
Risperidone—Hypersensitivity—Ezetimibe—atherosclerosis	0.0001	0.000642	CcSEcCtD
Risperidone—Asthenia—Lovastatin—atherosclerosis	9.94e-05	0.000637	CcSEcCtD
Risperidone—Pruritus—Lovastatin—atherosclerosis	9.8e-05	0.000628	CcSEcCtD
Risperidone—Asthenia—Ezetimibe—atherosclerosis	9.75e-05	0.000625	CcSEcCtD
Risperidone—Gastrointestinal pain—Niacin—atherosclerosis	9.73e-05	0.000624	CcSEcCtD
Risperidone—Nausea—Rosuvastatin—atherosclerosis	9.71e-05	0.000623	CcSEcCtD
Risperidone—Feeling abnormal—Pravastatin—atherosclerosis	9.66e-05	0.000619	CcSEcCtD
Risperidone—Pruritus—Ezetimibe—atherosclerosis	9.62e-05	0.000616	CcSEcCtD
Risperidone—Gastrointestinal pain—Pravastatin—atherosclerosis	9.58e-05	0.000614	CcSEcCtD
Risperidone—Hypersensitivity—Simvastatin—atherosclerosis	9.55e-05	0.000612	CcSEcCtD
Risperidone—Diarrhoea—Lovastatin—atherosclerosis	9.48e-05	0.000608	CcSEcCtD
Risperidone—Urticaria—Niacin—atherosclerosis	9.46e-05	0.000606	CcSEcCtD
Risperidone—Body temperature increased—Niacin—atherosclerosis	9.41e-05	0.000603	CcSEcCtD
Risperidone—Abdominal pain—Niacin—atherosclerosis	9.41e-05	0.000603	CcSEcCtD
Risperidone—Urticaria—Pravastatin—atherosclerosis	9.31e-05	0.000597	CcSEcCtD
Risperidone—Asthenia—Simvastatin—atherosclerosis	9.3e-05	0.000596	CcSEcCtD
Risperidone—Diarrhoea—Ezetimibe—atherosclerosis	9.3e-05	0.000596	CcSEcCtD
Risperidone—Abdominal pain—Pravastatin—atherosclerosis	9.26e-05	0.000594	CcSEcCtD
Risperidone—Body temperature increased—Pravastatin—atherosclerosis	9.26e-05	0.000594	CcSEcCtD
Risperidone—Pruritus—Simvastatin—atherosclerosis	9.17e-05	0.000588	CcSEcCtD
Risperidone—Dizziness—Lovastatin—atherosclerosis	9.16e-05	0.000587	CcSEcCtD
Risperidone—Dizziness—Ezetimibe—atherosclerosis	8.99e-05	0.000576	CcSEcCtD
Risperidone—Diarrhoea—Simvastatin—atherosclerosis	8.87e-05	0.000568	CcSEcCtD
Risperidone—Vomiting—Lovastatin—atherosclerosis	8.81e-05	0.000565	CcSEcCtD
Risperidone—Hypersensitivity—Niacin—atherosclerosis	8.77e-05	0.000562	CcSEcCtD
Risperidone—Rash—Lovastatin—atherosclerosis	8.74e-05	0.00056	CcSEcCtD
Risperidone—Dermatitis—Lovastatin—atherosclerosis	8.73e-05	0.00056	CcSEcCtD
Risperidone—Headache—Lovastatin—atherosclerosis	8.68e-05	0.000556	CcSEcCtD
Risperidone—Vomiting—Ezetimibe—atherosclerosis	8.64e-05	0.000554	CcSEcCtD
Risperidone—Hypersensitivity—Pravastatin—atherosclerosis	8.63e-05	0.000553	CcSEcCtD
Risperidone—Dizziness—Simvastatin—atherosclerosis	8.57e-05	0.000549	CcSEcCtD
Risperidone—Rash—Ezetimibe—atherosclerosis	8.57e-05	0.000549	CcSEcCtD
Risperidone—Dermatitis—Ezetimibe—atherosclerosis	8.56e-05	0.000549	CcSEcCtD
Risperidone—Asthenia—Niacin—atherosclerosis	8.54e-05	0.000547	CcSEcCtD
Risperidone—Headache—Ezetimibe—atherosclerosis	8.52e-05	0.000546	CcSEcCtD
Risperidone—Pruritus—Niacin—atherosclerosis	8.42e-05	0.00054	CcSEcCtD
Risperidone—Asthenia—Pravastatin—atherosclerosis	8.41e-05	0.000539	CcSEcCtD
Risperidone—ABCB1—liver—atherosclerosis	8.4e-05	0.00311	CbGeAlD
Risperidone—Pruritus—Pravastatin—atherosclerosis	8.29e-05	0.000531	CcSEcCtD
Risperidone—Vomiting—Simvastatin—atherosclerosis	8.24e-05	0.000528	CcSEcCtD
Risperidone—Nausea—Lovastatin—atherosclerosis	8.23e-05	0.000528	CcSEcCtD
Risperidone—Rash—Simvastatin—atherosclerosis	8.17e-05	0.000524	CcSEcCtD
Risperidone—Dermatitis—Simvastatin—atherosclerosis	8.17e-05	0.000523	CcSEcCtD
Risperidone—Diarrhoea—Niacin—atherosclerosis	8.14e-05	0.000522	CcSEcCtD
Risperidone—Headache—Simvastatin—atherosclerosis	8.12e-05	0.00052	CcSEcCtD
Risperidone—Nausea—Ezetimibe—atherosclerosis	8.07e-05	0.000517	CcSEcCtD
Risperidone—Diarrhoea—Pravastatin—atherosclerosis	8.02e-05	0.000514	CcSEcCtD
Risperidone—Dizziness—Niacin—atherosclerosis	7.87e-05	0.000504	CcSEcCtD
Risperidone—Dizziness—Pravastatin—atherosclerosis	7.75e-05	0.000497	CcSEcCtD
Risperidone—Nausea—Simvastatin—atherosclerosis	7.7e-05	0.000493	CcSEcCtD
Risperidone—Vomiting—Niacin—atherosclerosis	7.57e-05	0.000485	CcSEcCtD
Risperidone—Rash—Niacin—atherosclerosis	7.5e-05	0.000481	CcSEcCtD
Risperidone—Dermatitis—Niacin—atherosclerosis	7.5e-05	0.000481	CcSEcCtD
Risperidone—Headache—Niacin—atherosclerosis	7.46e-05	0.000478	CcSEcCtD
Risperidone—Vomiting—Pravastatin—atherosclerosis	7.45e-05	0.000478	CcSEcCtD
Risperidone—Rash—Pravastatin—atherosclerosis	7.39e-05	0.000474	CcSEcCtD
Risperidone—Dermatitis—Pravastatin—atherosclerosis	7.38e-05	0.000473	CcSEcCtD
Risperidone—Headache—Pravastatin—atherosclerosis	7.34e-05	0.000471	CcSEcCtD
Risperidone—Nausea—Niacin—atherosclerosis	7.07e-05	0.000453	CcSEcCtD
Risperidone—Nausea—Pravastatin—atherosclerosis	6.96e-05	0.000446	CcSEcCtD
Risperidone—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	2.94e-06	3.33e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	2.93e-06	3.32e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—VEGFA—atherosclerosis	2.93e-06	3.32e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—NOS3—atherosclerosis	2.91e-06	3.3e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—STAT3—atherosclerosis	2.9e-06	3.28e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	2.89e-06	3.27e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MMP9—atherosclerosis	2.89e-06	3.27e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—MTHFR—atherosclerosis	2.89e-06	3.27e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—VEGFA—atherosclerosis	2.88e-06	3.26e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CD36—atherosclerosis	2.87e-06	3.25e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—NFKB1—atherosclerosis	2.86e-06	3.24e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—STAT3—atherosclerosis	2.85e-06	3.23e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MMP9—atherosclerosis	2.85e-06	3.23e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—MAPK3—atherosclerosis	2.85e-06	3.23e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	2.85e-06	3.23e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—CXCL8—atherosclerosis	2.84e-06	3.22e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PPARA—atherosclerosis	2.83e-06	3.21e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—MAPK3—atherosclerosis	2.83e-06	3.21e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.82e-06	3.2e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—NFKB1—atherosclerosis	2.82e-06	3.2e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MAPK8—atherosclerosis	2.81e-06	3.18e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	2.81e-06	3.18e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling by GPCR—AKT1—atherosclerosis	2.8e-06	3.17e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	2.8e-06	3.17e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	2.8e-06	3.17e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—ALB—atherosclerosis	2.79e-06	3.16e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—INS—atherosclerosis	2.77e-06	3.14e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MAPK8—atherosclerosis	2.77e-06	3.14e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—MAPK3—atherosclerosis	2.77e-06	3.14e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling by GPCR—AKT1—atherosclerosis	2.76e-06	3.13e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TGFB1—atherosclerosis	2.76e-06	3.13e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	2.75e-06	3.12e-05	CbGpPWpGaD
Risperidone—ADRA2B—GPCR downstream signaling—AKT1—atherosclerosis	2.75e-06	3.11e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	2.75e-06	3.11e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TGFB1—atherosclerosis	2.74e-06	3.11e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	2.74e-06	3.11e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AGT—atherosclerosis	2.74e-06	3.11e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	2.73e-06	3.1e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	2.73e-06	3.09e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—MAPK3—atherosclerosis	2.73e-06	3.09e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—STAT3—atherosclerosis	2.72e-06	3.09e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—MTHFR—atherosclerosis	2.72e-06	3.08e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NOS3—atherosclerosis	2.72e-06	3.08e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—IL6—atherosclerosis	2.71e-06	3.07e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TGFB1—atherosclerosis	2.69e-06	3.04e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—APOE—atherosclerosis	2.69e-06	3.04e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	2.68e-06	3.04e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	2.67e-06	3.03e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NOS3—atherosclerosis	2.67e-06	3.02e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARA—atherosclerosis	2.67e-06	3.02e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—NOS3—atherosclerosis	2.67e-06	3.02e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTGS2—atherosclerosis	2.66e-06	3.02e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—CAV1—atherosclerosis	2.66e-06	3.02e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	2.66e-06	3.01e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—APOA1—atherosclerosis	2.66e-06	3.01e-05	CbGpPWpGaD
Risperidone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	2.65e-06	3.01e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TGFB1—atherosclerosis	2.64e-06	3e-05	CbGpPWpGaD
Risperidone—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	2.64e-06	2.99e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	2.62e-06	2.97e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CXCL8—atherosclerosis	2.62e-06	2.96e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	2.61e-06	2.96e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	2.6e-06	2.95e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.6e-06	2.94e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—VEGFA—atherosclerosis	2.59e-06	2.94e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AGT—atherosclerosis	2.58e-06	2.93e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MMP9—atherosclerosis	2.57e-06	2.92e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—STAT3—atherosclerosis	2.57e-06	2.91e-05	CbGpPWpGaD
Risperidone—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	2.57e-06	2.91e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—VEGFA—atherosclerosis	2.56e-06	2.9e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	2.55e-06	2.89e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—NFKB1—atherosclerosis	2.55e-06	2.88e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—STAT3—atherosclerosis	2.53e-06	2.87e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—APOE—atherosclerosis	2.53e-06	2.87e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	2.53e-06	2.86e-05	CbGpPWpGaD
Risperidone—ADRA1B—GPCR downstream signaling—AKT1—atherosclerosis	2.53e-06	2.86e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	2.52e-06	2.86e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.52e-06	2.85e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—CAV1—atherosclerosis	2.51e-06	2.84e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK8—atherosclerosis	2.5e-06	2.84e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—APOA1—atherosclerosis	2.5e-06	2.84e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling by GPCR—AKT1—atherosclerosis	2.5e-06	2.83e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—IL6—atherosclerosis	2.49e-06	2.82e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	2.48e-06	2.81e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.47e-06	2.8e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	2.46e-06	2.78e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MAPK3—atherosclerosis	2.45e-06	2.78e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.44e-06	2.77e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTGS2—atherosclerosis	2.44e-06	2.76e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	2.43e-06	2.76e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CG—atherosclerosis	2.42e-06	2.75e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MAPK3—atherosclerosis	2.42e-06	2.74e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	2.42e-06	2.74e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCL8—atherosclerosis	2.41e-06	2.73e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	2.41e-06	2.73e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	2.4e-06	2.72e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.4e-06	2.72e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.4e-06	2.72e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TGFB1—atherosclerosis	2.38e-06	2.7e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	2.38e-06	2.69e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.37e-06	2.69e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCL8—atherosclerosis	2.37e-06	2.68e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MMP9—atherosclerosis	2.37e-06	2.68e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TGFB1—atherosclerosis	2.35e-06	2.66e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NFKB1—atherosclerosis	2.34e-06	2.65e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PPARG—atherosclerosis	2.34e-06	2.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	2.34e-06	2.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	2.33e-06	2.64e-05	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	2.33e-06	2.64e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	2.32e-06	2.63e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—VEGFA—atherosclerosis	2.31e-06	2.62e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK8—atherosclerosis	2.3e-06	2.61e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—INS—atherosclerosis	2.29e-06	2.6e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—AKT1—atherosclerosis	2.29e-06	2.6e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—IL6—atherosclerosis	2.29e-06	2.6e-05	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	2.29e-06	2.6e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—STAT3—atherosclerosis	2.29e-06	2.59e-05	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	2.29e-06	2.59e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CG—atherosclerosis	2.28e-06	2.59e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	2.26e-06	2.56e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—IL6—atherosclerosis	2.25e-06	2.55e-05	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	2.24e-06	2.54e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	2.23e-06	2.53e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.22e-06	2.51e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	2.21e-06	2.5e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	2.21e-06	2.5e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARG—atherosclerosis	2.2e-06	2.5e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.2e-06	2.49e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MAPK3—atherosclerosis	2.19e-06	2.48e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MMP9—atherosclerosis	2.18e-06	2.47e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—INS—atherosclerosis	2.16e-06	2.45e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.16e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	2.16e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	2.16e-06	2.45e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NFKB1—atherosclerosis	2.16e-06	2.44e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.15e-06	2.43e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MMP9—atherosclerosis	2.14e-06	2.43e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	2.14e-06	2.42e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—atherosclerosis	2.12e-06	2.41e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.12e-06	2.41e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK8—atherosclerosis	2.12e-06	2.4e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TGFB1—atherosclerosis	2.12e-06	2.4e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NFKB1—atherosclerosis	2.12e-06	2.4e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—AKT1—atherosclerosis	2.12e-06	2.4e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	2.11e-06	2.39e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—ALB—atherosclerosis	2.1e-06	2.38e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—STAT3—atherosclerosis	2.1e-06	2.38e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	2.1e-06	2.38e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.1e-06	2.38e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.09e-06	2.36e-05	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	2.09e-06	2.36e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.08e-06	2.36e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—IL6—atherosclerosis	2.08e-06	2.36e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.08e-06	2.36e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.08e-06	2.36e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.08e-06	2.35e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—IL6—atherosclerosis	2.07e-06	2.34e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—APOB—atherosclerosis	2.07e-06	2.34e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	2.05e-06	2.33e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	2.05e-06	2.32e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.04e-06	2.32e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	2.04e-06	2.31e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.04e-06	2.31e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.04e-06	2.31e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—IL6—atherosclerosis	2.03e-06	2.29e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—NOS3—atherosclerosis	2.01e-06	2.28e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.01e-06	2.28e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MAPK3—atherosclerosis	2.01e-06	2.28e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—IL6—atherosclerosis	1.99e-06	2.26e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—ALB—atherosclerosis	1.98e-06	2.25e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.98e-06	2.24e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—LPL—atherosclerosis	1.97e-06	2.24e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.96e-06	2.22e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.95e-06	2.21e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TGFB1—atherosclerosis	1.95e-06	2.21e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.94e-06	2.2e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.93e-06	2.19e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.93e-06	2.18e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—GPX1—atherosclerosis	1.93e-06	2.18e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—atherosclerosis	1.92e-06	2.18e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT1—atherosclerosis	1.92e-06	2.18e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.91e-06	2.16e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT1—atherosclerosis	1.91e-06	2.16e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—STAT3—atherosclerosis	1.9e-06	2.16e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—IL6—atherosclerosis	1.9e-06	2.16e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.9e-06	2.15e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—NOS3—atherosclerosis	1.9e-06	2.15e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.89e-06	2.15e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	1.89e-06	2.14e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CD36—atherosclerosis	1.88e-06	2.13e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	1.87e-06	2.12e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT1—atherosclerosis	1.87e-06	2.12e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.85e-06	2.1e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—atherosclerosis	1.84e-06	2.09e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT1—atherosclerosis	1.84e-06	2.08e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.82e-06	2.07e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MAPK3—atherosclerosis	1.82e-06	2.06e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.8e-06	2.04e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—IL6—atherosclerosis	1.79e-06	2.03e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	1.78e-06	2.02e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.78e-06	2.01e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—IL6—atherosclerosis	1.77e-06	2.01e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.77e-06	2e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TGFB1—atherosclerosis	1.76e-06	2e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT1—atherosclerosis	1.75e-06	1.99e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.75e-06	1.99e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARA—atherosclerosis	1.74e-06	1.98e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.74e-06	1.97e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—atherosclerosis	1.73e-06	1.97e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	1.73e-06	1.96e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—AKT1—atherosclerosis	1.7e-06	1.92e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AGT—atherosclerosis	1.69e-06	1.91e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.66e-06	1.88e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.65e-06	1.88e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—APOE—atherosclerosis	1.65e-06	1.88e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—AKT1—atherosclerosis	1.65e-06	1.87e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—CAV1—atherosclerosis	1.64e-06	1.86e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—APOA1—atherosclerosis	1.64e-06	1.85e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT1—atherosclerosis	1.63e-06	1.85e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.61e-06	1.82e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—IL6—atherosclerosis	1.6e-06	1.81e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.54e-06	1.75e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.53e-06	1.74e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.49e-06	1.69e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.49e-06	1.69e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT1—atherosclerosis	1.47e-06	1.67e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—IL6—atherosclerosis	1.47e-06	1.66e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARG—atherosclerosis	1.44e-06	1.63e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.61e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.42e-06	1.6e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—INS—atherosclerosis	1.41e-06	1.6e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.38e-06	1.56e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT1—atherosclerosis	1.36e-06	1.54e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—IL6—atherosclerosis	1.35e-06	1.53e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—AKT1—atherosclerosis	1.34e-06	1.52e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.33e-06	1.51e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—IL6—atherosclerosis	1.33e-06	1.51e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.3e-06	1.48e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—ALB—atherosclerosis	1.3e-06	1.47e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT1—atherosclerosis	1.25e-06	1.42e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—NOS3—atherosclerosis	1.24e-06	1.4e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.23e-06	1.39e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.23e-06	1.39e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—AKT1—atherosclerosis	1.23e-06	1.39e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	1.21e-06	1.37e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.2e-06	1.36e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.13e-06	1.28e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.12e-06	1.27e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AKT1—atherosclerosis	9.25e-07	1.05e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKT1—atherosclerosis	8.72e-07	9.88e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKT1—atherosclerosis	5.7e-07	6.46e-06	CbGpPWpGaD
